ProCE Banner Activity

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: A Pharmacist’s Perspective

Slideset Download

Download this slideset presenting a pharmacist perspective on key data and toxicity management strategies for optimal use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Released: October 13, 2021

Share

Faculty

Stefanie L. Houseknecht

Stefanie L. Houseknecht, PharmD, BCOP

Clinical Pharmacy Specialist
Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Stefanie L. Houseknecht, PharmD, BCOP

Clinical Pharmacy Specialist
Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland

Stefanie Houseknecht, PharmD, BCOP, has no relevant conflicts of interest to report.